R & D Pipeline
Our lead cancer product, PRP, is in the preclinical development stage.
The present focus of the development of PRP is to create an anti-cancer product that is effective in treating cancer, and which is sufficiently well tolerated to be suitable for chronic, long term use in patients with diagnosed cancer, and potentially in the longer term in patients at high risk of developing cancer.
An additional opportunity for PRP is in the treatment of solid tumor masses by the direct injection of PRP into those tumor masses. In order to achieve this, Propanc is developing an injectable form of PRP (PRP Injection) which would be suitable for direct injection into tumor masses, the intention being to cause shrinkage of individual problematic tumor masses.
A research program, POP1, has been established with Propanc’s collaborators to investigate the changes in genetic and protein expression which occur in cancer cells as a consequence to being exposed to Propanc’s proteolytic proenzyme formulation.
The objective of this work is to understand at the molecular level the targets of Propanc's proteolytic proenzyme formulation, thereby providing the opportunity for new, patentable drugs which can be further developed by Propanc.
Propanc's R&D pipeline
